Navigation Links
Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis
Date:3/4/2010

To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.

In vitro cultivated ICCBco is composed of Calculus Bovis, Chinese Paris Rhizome, polygonum cuspidatum, appendiculate cremastra pseudobulb, frankincense, and myrrh, and has the functions of clearing away heat and toxic materials, removing blood stasis, reducing swelling, eliminating blood stasis and promoting tissue regeneration, according to the principle of traditional Chinese medicine. However, the topic has not been unequivocally addressed.

A research article published on February 14, 2010 in the World Journal of Gastroenterology addresses this question. The group led by Tao Li, MD, evaluated the efficacy of ICCBco in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model. They explored the pathogenesis of portal hypertension and the prevention and treatment of its pulmonary complications (hepatopulmonary syndrome, pulmonary fibrosis, pulmonary hypertension, pulmonary venous hypertension) from a new perspective of portal hypertensive vascular disease. Calculus Bovis is a Class 1 new Chinese medicine developed by Wuhan Tongji Hospital with independent intellectual property rights, is a treasure of traditional Chinese medicine. To investigate its role in the treatment of schistosomiasis-induced pulmonary complications of portal hypertension has far-reaching significance.

The successful development of Calculus Bovis and the preliminary study on portal hypertensive pulmonary lesions caused by schistosomiasis suggest that it is of great significance and prospects for further basic and clinical research, development and clinical application of new drugs and preparations to treat portal hypertensive pulmonary lesions induced by schistosomiasis.


'/>"/>

Contact: Jin-Lei Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. New Alzheimers Prevention Efforts, and Non-Drug Treatments, Featured at 25th Conference of Alzheimers Disease International
2. Montecatini Eating Disorders Program Announces 'Log In & Learn' Webinar Series for Treatment Professionals
3. Targeting leukemia cells gene addiction presents new strategy for treatment
4. BioCosmetic Center Utilizes FDA Approved Fractional Laser Treatment for Stretch Marks
5. PINC trial launched to test new treatment for pre-invasive breast cancer
6. New Treatment Eyed for Deadly Pancreatic Cancer
7. Connecticut Governor Jodi Rell Honors Mountainside Addiction Treatment Center for its Twelve Years of Operating in Connecticut
8. Blacks less likely to know they have heart condition or to use treatment for it, says Mayo Clinic
9. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
10. New CASA* Report Finds: 65 Percent of All U.S. Inmates Meet Medical Criteria for Substance Abuse Addiction, Only 11 Percent Receive Any Treatment
11. Groundbreaking Study Using Ultrasound for the Treatment of Intracerebral and Intraventricular Hemorrhage Stroke Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Dallas, Texas (PRWEB) , ... February 17, 2017 , ... ... Arden Moore’s “Oh Behave” Show on the Pet Life Radio network. The episode, ... explores a number of topics including: what factors led to Park Cities Pet Sitter’s ...
(Date:2/17/2017)... Murfreesboro, TN (PRWEB) , ... February 17, 2017 ... ... EHR mobility has not kept pace. Enovate Medical has introduced an innovative workstation ... 20 years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, ...
(Date:2/17/2017)... (PRWEB) , ... February 17, ... ... Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — ... are the critical reimbursement questions manufacturers should be asking before selecting an ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... at the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to ... of the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, ... George Rogers, was named to Staffing Industry Analysts' 2017 "Staffing 100 North America" ... who have made notable contributions to the staffing industry over the last twelve ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  BioDigital, Inc., creators of the ... their 3D body mapping technology with eClinicalWorks, a ... integration will be used to capture and present ... the human body. BioDigital pilots show using a ... also increasing the precision of clinical annotations compared ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
(Date:2/16/2017)... Research and Markets has announced the ... Technologies" report to their offering. ... Traditional medical devices include ... non-drug coated implantables, large endoscopes, needle based drug delivery, lab ... last two to three decades for the treatment and management ...
Breaking Medicine Technology: